Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases

Guo, Jingfei; Zhang, Qian; Bi, Xinyu; Zhou, Jianguo; Li, Zhiyu; Huang, Zhen; Zhang, Yefan; Li, Muxing; Chen, Xiao; Hu, Xuhui; Chi, Yihebali; Liang, Junbo; Liu, Jianmei; Zhao, Jianjun; Cai, Jianqiang; Zhao, Hong

doi:10.18632/oncotarget.14156

Cited by 21 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, PTR was safe with a low perioperative risk of mortality (53). However, due to the scarcity of randomized controlled trials, the decision to implement PTR, particularly in asymptomatic patients with the inoperable metastatic condition, should still be made on an individual basis (54).…”

Section: Treatmentmentioning

confidence: 99%

VIPoma: Mechanisms, clinical presentation, diagnosis and treatment (Review)

Abdullayeva

2019

Wrld Acd Sci

View full text Add to dashboard Cite

Vasoactive intestinal peptide (VIP) secreting tumour (VIPoma) is a rare neuroendocrine tumour that most often originates from pancreatic islet cells and affects one in ten million individuals per year. In adults, it develops most commonly in the fortieth year of life with a sparse female predominance. Excessive VIP secretion induces refractory watery diarrhoea, hypokalemia and achlorhydria. Other symptoms include hyperglycemia (20-50%), hypercalcaemia (25-50%), hypochlorhydria (20-50%) and flushing (15-30%). VIP plasma levels are increased in almost all patients with VIPoma, and, together with profusing secretory diarrhoea, it is sufficient to establish the diagnosis. Moreover, the majority of VIPomas are malignant or have already metastasised at the time of diagnosis. The treatment of the neoplasm comprises medical management and surgery. While surgery remains the gold standard of treatment, peptide receptor radionuclide therapy represents one of the most effective and well-tolerated treatment options. The average survival rate of patients with VIPoma is 96 months. The objective of this review was to summarise all features of pancreatic VIPoma, as well as present novel treatment approaches for this rare neoplasm.

show abstract

Section: Treatmentmentioning

confidence: 99%

VIPoma: Mechanisms, clinical presentation, diagnosis and treatment (Review)

Abdullayeva

2019

Wrld Acd Sci

View full text Add to dashboard Cite

show abstract

“…Resection of stage IV primary tumour with non--resectable hepatic metastases is under consideration [162] (*evidence level 3).…”

Section: Surgical Treatmentmentioning

confidence: 99%

Zalecenia ogólne dotyczące postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Kos–Kudła

Blicharz-Dorniak²,

Strzelczyk³

et al. 2017

Endokrynologia Polska

View full text Add to dashboard Cite

Progress in the diagnostics and therapy of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN), the published results of new randomised clinical trials, and the new guidelines issued by the European Neuroendocrine Tumour Society (ENETS) have led the Polish Network of Neuroendocrine Tumours to update the 2013 guidelines regarding management of these neoplasms. We present the general recommendations for the management of NENs, developed by experts during the Third Round Table Conference - Diagnostics and therapy of gastro-entero-pancreatic neuroendocrine neoplasms: Polish recommendations in view of current European recommenda-tions, which took place in December 2016 in Żelechów near Warsaw. Drawing from the extensive experience of centres dealing with this type of neoplasms, we hope that we have managed to develop the optimal management system, applying the most recent achievements in the field of medicine, for these patients, and that it can be implemented effectively in Poland. These management guidelines have been arranged in the following order: gastric and duodenal NENs (including gastrinoma); pancreatic NENs; NENs of the small intestine and appendix, and colorectal NENs.

show abstract

“…Nach aktueller Datenlage ist auch in der palliativen Situation die Resektion des Primarius und die Lymphadenektomie sinnvoll [1,2] …”

Section: Hintergrund Und Fragestellung Bei Den Neuroendokrinen Tumorunclassified

Metastasierte neuroendokrine Dünndarmtumoren: Ileusprophylaktische Operation

Weber

Dralle

2018

Chirurg

View full text Add to dashboard Cite

Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases

Cited by 21 publications

References 35 publications

VIPoma: Mechanisms, clinical presentation, diagnosis and treatment (Review)

VIPoma: Mechanisms, clinical presentation, diagnosis and treatment (Review)

Zalecenia ogólne dotyczące postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Metastasierte neuroendokrine Dünndarmtumoren: Ileusprophylaktische Operation

Contact Info

Product

Resources

About